OUR COMPANY
We are what we do
Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and Torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
OUR PEOPLE
Here’s our who’s who
MANAGEMENT TEAM
Someit Sidhu, M.D.
Chris Cabell, M.D.
Chief Medical Officer and Head of R&D
Gary Whale, Ph.D.
Kim Davis
Chief Legal Officer
Kiran Nistala, M.B.B.S., Ph.D.
Executive Vice President
Michael Howell, Ph.D.
Chief Scientific Officer and Head of Translational Science
Chief Financial Officer
BOARD OF DIRECTORS
Amit Munshi
Chairman
Independent Director
Jen Jarrett
Independent Director
Neil Graham, M.D.
Independent Director
Independent Director
Sandeep Kulkarni, M.D.
Independent Director
Someit Sidhu, M.D.
Chief Executive Officer and Director
Steve Schoch
Independent Director